Literature DB >> 2703838

Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

B Pillon1, B Dubois, G Cusimano, A M Bonnet, F Lhermitte, Y Agid.   

Abstract

In order to investigate the neuronal basis of cognitive disorders in Parkinson's disease, the neuropsychological performance of 120 patients with idiopathic Parkinson's disease was analysed in relation to motor symptoms as a function of their response to levodopa. Cognitive impairment was poorly correlated with akinesia and rigidity, symptoms which respond well to levodopa treatment, and was not correlated at all with that part of the patients' motor score that could be improved by the drug. In contrast, strong correlations were found between all neuropsychological test scores and axial symptoms such as gait disorder and dysarthria, which respond little if at all to levodopa treatment. The neuropsychological test scores were also strongly correlated with the motor score of patients estimated when clinical improvement was maximal under levodopa treatment. This score is assumed to represent residual non-dopaminergic motor dysfunctions. The correlations suggest that much of the cognitive impairment in Parkinson's disease results from the dysfunction of non-dopaminergic neuronal systems.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703838      PMCID: PMC1032506          DOI: 10.1136/jnnp.52.2.201

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz; K Jellinger; F Seitelberger
Journal:  J Neurol Sci       Date:  1973-12       Impact factor: 3.181

2.  Psychiatric disturbances in Parkinson's disease.

Authors:  G G Celesia; W M Wanamaker
Journal:  Dis Nerv Syst       Date:  1972-09

3.  Intellectual impairment in Parkinson's syndrome.

Authors:  A W Loranger; H Goodell; F H McDowell; J E Lee; R D Sweet
Journal:  Brain       Date:  1972       Impact factor: 13.501

4.  Intellectual functioning of persons with idiopathic Parkinsonism.

Authors:  D C Garron; H L Klawans; F Narin
Journal:  J Nerv Ment Dis       Date:  1972-06       Impact factor: 2.254

5.  Levodopa treatment of Parkinson's syndrome. Improved intellectual functioning.

Authors:  A W Loranger; H Goodell; J E Lee; F McDowell
Journal:  Arch Gen Psychiatry       Date:  1972-02

6.  Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease.

Authors:  R D Rafal; M I Posner; J A Walker; F J Friedrich
Journal:  Brain       Date:  1984-12       Impact factor: 13.501

7.  Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease.

Authors:  R G Brown; C D Marsden; N Quinn; M A Wyke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

8.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

9.  A subcortico-cortical cholinergic system is affected in Parkinson's disease.

Authors:  B Dubois; M Ruberg; F Javoy-Agid; A Ploska; Y Agid
Journal:  Brain Res       Date:  1983-12-12       Impact factor: 3.252

10.  Levodopa, parkinsonism, and recent memory.

Authors:  R Halgin; M Riklan; H Misiak
Journal:  J Nerv Ment Dis       Date:  1977-04       Impact factor: 2.254

View more
  32 in total

Review 1.  The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.

Authors:  Claudio Da Cunha; Miriam Elizabeth Mendes Angelucci; Newton S Canteras; Susan Wonnacott; Reinaldo N Takahashi
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

2.  Handedness and motor symptom asymmetry in Parkinson's disease.

Authors:  Matthew J Barrett; Scott A Wylie; Madaline B Harrison; G Frederick Wooten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-22       Impact factor: 10.154

Review 3.  Deterioration of dopaminergic pathways and alterations in cognition and motor functions.

Authors:  B Dubois; B Pillon; Y Agid
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

4.  Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease.

Authors:  N Wolfe; D I Katz; M L Albert; A Almozlino; R Durso; M C Smith; L Volicer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

5.  Cognitive improvement during Tolcapone treatment in Parkinson's disease.

Authors:  M Gasparini; E Fabrizio; V Bonifati; G Meco
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  The cortical cholinergic system contributes to the top-down control of distraction: Evidence from patients with Parkinson's disease.

Authors:  Kamin Kim; Martijn L T M Müller; Nicolaas I Bohnen; Martin Sarter; Cindy Lustig
Journal:  Neuroimage       Date:  2017-12-19       Impact factor: 6.556

Review 7.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

8.  New MRI Biomarkers Advance the Characterization of Parkinson Disease.

Authors:  David A Ziegler; Suzanne Corkin
Journal:  Eur Neurol Rev       Date:  2013

9.  Anticholinergic therapy and dementia in patients with Parkinson's disease.

Authors:  M Pondal; T Del Ser; F Bermejo
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

10.  Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms.

Authors:  David A Ziegler; Paymon Ashourian; Julien S Wonderlick; Alison K Sarokhan; Drazen Prelec; Clemens R Scherzer; Suzanne Corkin
Journal:  Scand J Psychol       Date:  2014-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.